RANI · Rani Therapeutics Holdings, Inc.

Track RANI — free

$0.84 +0.02 (+2.51%) At close · Sep 11

Rebalance outlook locked

Market Cap

$117.45M

139.40M

Up next

Next earnings call

Mar 23, 2027 Est · unconfirmed · in 27 wks

Latest filing: 10-Q

filed Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$4.88M

Trailing 12 months

Net income (TTM)

−$24.67M

Trailing 12 months

Revenue growth YoY

+58.9%

Year over year

Operating margin

-675.8%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-17.3%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+412.2%

Year over year · more shares

Price change (1Y)

+66.9%

Trailing year

Short interest

4.6%

Latest settlement · 8.1 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 15.8 · calm Equity put/call 0.58

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg −21%

below

Price vs 50-day avg +5%

above

RSI (14) 51

neutral

MACD trend Negative

52-week position 16%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Weak

1-month return +6%

trailing

6-month return −25%

trailing

YTD return −38%

this year

Relative strength −43%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $1 › 200d $1 — 200d above 50d

Institutional flow Distributing

-11% holders QoQ · +10 funds added

Insider flow Accumulating

Net +$50.0K over 90 days · 0% sells

Short interest Falling

4.58% of float · ▼ -21.7% MoM · 8.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

68 holders — mid 3-yr range

Squeeze score 66

elevated · 0–100

Fundamentals

Strong

Revenue growth +59%

Y/Y

EPS growth +57%

Y/Y

Free cash flow $-18.8M

Balance sheet $18.6M

net cash

Quant / Vol

risk profile

Very High

Volatility 273%

annualized · 1-yr

Max drawdown −78%

past year

ATR 5.6%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral

2 · 4 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−21% Bearish

Price vs 50-day avg

+5% Bullish

RSI (14)

51 Neutral

MACD trend

Negative Bearish

52-week position

16% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $1 › 200d $1 — 200d above 50d

Institutional flow Distributing

-11% holders QoQ · +10 funds added

Insider flow Accumulating

Net +$50.0K over 90 days · 0% sells

Short interest Falling

4.58% of float · ▼ -21.7% MoM · 8.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

68 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $0 Now $1 · 16% Range high $3

vs 200-day avg -21% vs 50-day avg +5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
RANI Rani Therapeutics Holdings, Inc. this stock	$117.45M	-37.6%	+58.9%	—	4.6%
VRTX Vertex Pharmaceuticals Inc / Ma	$130.64B	+13.7%	+46.2%	30.0	1.8%
REGN Regeneron Pharmaceuticals, Inc.	$80.46B	+1.2%	+20.8%	19.4	2.5%
ARGX Argenx SE	$61.22B	+17.1%	—	—	2.0%
MRNA Moderna, Inc.	$57.48B	+388.2%	+4.3%	—	9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

% held: 32.8%
Net QoQ: +1.3M sh
Top holder: SAMSARA BIOCAPITAL, LLC

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Falling

Shares short

6.4M

Days to cover: 8.1d
Change: -1.8M sh

View

Short Volume

Short vol %

78%

As of: Sep 11, 2026

Short Total

View

Fails to Deliver

FTD shares

1.4K

Value: $1.1K
As of: Aug 12, 2026

View

Off-Exchange

Off-exchange %

65.3%

Week of: Aug 3, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net buying

Net (90d)

+$50.0K

Buyers / Sellers: 2 / 0

Buyers Sellers

View

Financials

Revenue (FY)

$1.6M

Net income (FY): $-29.7M
EPS diluted: $-0.45

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 13, 2026
This year: 14

View

Exempt Offerings

Offering

$60.3M

Filed: Nov 10, 2025

View

Earnings & Events

Earnings Calls

Last call

Aug 12, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
RANI	-1.1%	+5.6%	-25.4%	-1.3%	-37.6%
SPY	-1.2%	-1.8%	+17.8%	-0.4%	+12.1%
vs SPY	+0.0%	+7.4%	-43.3%	-1.0%	-49.7%

Key facts CIK 1856725 CUSIP 753018100 13F (30d) 22 filings 22 filers Visit website Investor relations

RANI · Rani Therapeutics Holdings, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance